Citadel Advisors
ADCT icon

Citadel Advisors’s ADC Therapeutics ADCT Stock Holding History

Citadel Advisors’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,600
Closed -$78.4K – 12524
2025
Q3 		$78.4K Buy
19,600
+800
+4% +$2.52K ﹤0.01% 11986
2025
Q2 		$50.4K Buy
18,800
+11,200
+147% +$23.6K ﹤0.01% 11765
2025
Q1 		$10.7K Sell
7,600
-8,200
-52% -$13.9K ﹤0.01% 13527
2024
Q4 		$31.4K Sell
15,800
-15,700
-50% -$41.1K ﹤0.01% 12828
2024
Q3 		$99.2K Buy
31,500
+3,000
+11% +$9.46K ﹤0.01% 11124
2024
Q2 		$90.1K Buy
28,500
+1,400
+5% +$5.56K ﹤0.01% 11065
2024
Q1 		$122K Buy
27,100
+25,400
+1,494% +$93.7K ﹤0.01% 11087
2023
Q4 		$2.82K Sell
1,700
-3,700
-69% -$3.41K ﹤0.01% 13651
2023
Q3 		$4.84K Sell
5,400
-5,700
-51% -$7.58K ﹤0.01% 13445
2023
Q2 		$23.9K Sell
11,100
-700
-6% -$1.57K ﹤0.01% 12581
2023
Q1 		$23K Buy
11,800
+3,800
+48% +$14K ﹤0.01% 12960
2022
Q4 		$30.7K Buy
+8,000
New +$32K ﹤0.01% 12718
2022
Q3 		– Sell
-14,700
Closed -$117K – 12496
2022
Q2 		$117K Buy
14,700
+2,900
+25% +$27.4K ﹤0.01% 11245
2022
Q1 		$173K Buy
+11,800
New +$187K ﹤0.01% 11689
2021
Q3 		– Sell
-27,000
Closed -$657K – 13718
2021
Q2 		$657K Buy
27,000
+2,600
+11% +$60.3K ﹤0.01% 9396
2021
Q1 		$596K Buy
+24,400
New +$707K ﹤0.01% 9300

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's ADCT Position: Q1 2026 in Review

Citadel Advisors increased its ADC Therapeutics (ADCT) stake by 34% in Q1 2026, buying an estimated $400K and bringing the position to 399,721 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6709.

Citadel Advisors first reported a position in ADCT in Q2 2020 and has held it in 17 quarters since. The position peaked at $7.63M in Q4 2022. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Citadel Advisors held 399,721 shares of ADC Therapeutics worth $1.5M as of Q1 2026.
  • Citadel Advisors bought 101,503 ADC Therapeutics shares in Q1 2026, an estimated $400K.
  • ADC Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6709 holding.
  • Citadel Advisors first reported a position in ADC Therapeutics in Q2 2020 and has held it in 17 quarters since.
  • Citadel Advisors's ADC Therapeutics position peaked at $7.63M in Q4 2022.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.